Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
dna ligase WKY and SHR strains have important differences ma
2025-01-07

WKY and SHR strains have important differences mainly in their sympathetic status but also in the activity of the RAS. The development of hypertension in SHR is clearly related to an increase in sympathetic activity [51], [11]. In addition, increased renal sympathetic nerve activity led to an increa
-
br Development of lorlatinib from crizotinib to
2025-01-07

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
Glycerol dehydratase GDHt EC is
2025-01-07

Glycerol dehydratase (GDHt, EC 4.2.1.30) is a key enzyme for the bioconversion of glycerol into the value-added chemicals and thereby has recently attracted a great deal of attention as an essential component for metabolic engineering . GDHt carries out a radical-mediated turnover of glycerol into 3
-
Thus far clinical data indicate that IDO inhibitors have man
2025-01-07

Thus far, clinical data indicate that IDO1 inhibitors have manageable toxicity, albeit with a relatively short period of treatment in a small number of patients. KYN is a pluripotent mediator and key intermediate for the synthesis of a host of downstream KP metabolites that are implicated in inflamm
-
The role of circulating physiologic concentrations of FGF in
2025-01-07

The role of circulating physiologic concentrations of FGF21 in glucose metabolism, however, remains unclear. Circulating FGF21 levels in obese and diabetic rodents, and in patients with type 2 diabetes are significantly higher than those in controls without diabetes [4], [5], [6]. On the other hand,
-
Several reports of single cases of MG patients treated
2025-01-07

Several reports of single cases of MG patients treated with Rituximab have claimed a favourable response (Baek et al., 2007, Gajra et al., 2004, Hain et al., 2006, Thakre et al., 2007, Wylam et al., 2003, Zaja et al., 2000). We report our experience with Rituximab in 6 patients with severe MG, 3 pa
-
Finally one can ask whether
2025-01-07

Finally, one can ask whether these results throw any light on the nature of the target in SNMG patients. Interestingly, the results of the in vitro incubations suggested that SNMG sera might increase AChR expression to a small extent, raising the possibility that SNMG patients, who have thymic chang
-
br Conflict of interest br Acknowledgments This work was bee
2025-01-06

Conflict of interest Acknowledgments This work was been partially supported by the following grants: C.I.S.I.A. project (Innovazione e Sviluppo del Mezzogiorno—Conoscenze Integrate per Sostenibilità ed Innovazione del Made in Italy Agroalimentare—Legge 191/2009) from the Italian Ministry of Ec
-
As in humans and other mammalians
2025-01-06

As in humans and other mammalians spontaneous activity of sinoatrial pacemaker ezh2 inhibitor in in the zebrafish heart crucially depends on proper HCN4 channel activity (If) and spontaneous diastolic depolarization [15,81]. Whether Na+/K+-ATPase currents regulate next to phase of myocardial repolar
-
It has been shown that ACLY is localized to
2025-01-06

It has been shown that ACLY is localized to not only the cytoplasm but also the nucleus. Nuclear ACLY may supply acetyl-CoA for histone acetylation, leading to global regulation of the gene expression [16], [18]. We previously reported that AZ2 is also localized to both the cytoplasm and nucleus whe
-
Although the LB domains of
2025-01-06

Although the LB2 domains of mGlu receptors have not been shown to form an extensive interface during activation, they do draw closer to each other, as demonstrated in crystal structures (Kunishima et al., 2000, Muto et al., 2007, Tsuchiya et al., 2002) and by FRET analysis (Doumazane et al., 2013, V
-
Analysis of ASK crystal structures as
2025-01-06

Analysis of ASK1 crystal structures as well as an investigation of how Steroidogenesis inhibitor 4 might bind were undertaken to understand opportunities for engaging Gln756. To this end a docking model derived from PDB 3VW622 was used to predict the binding mode of amide 4 in the ASK1 active site
-
Growth inhibition assays are the most commonly used to ident
2025-01-06

Growth-inhibition assays are the most commonly used to identify antifungal small molecules. However, they have several facts that limit their use since many pathogenic fungi grow as filaments making difficult a correlation between growth and OD (optical density). They are not useful for identifying
-
Vascular interventional radiology VIR laboratories
2025-01-06

Vascular interventional radiology (VIR) laboratories perform a myriad of procedures ranging from simple tunneled peripherally inserted central catheter lines to complex transjugular intrahepatic portosystemic shunt placements. Infections are a common complication in the VIR environment; thus, the pr
-
Biochanin A Benefits VEGFR inhibition using sunitinib does n
2025-01-06

VEGFR2 inhibition using sunitinib does not result in tumor growth reduction or in a further decrease in vessel density in NDRG1 overexpressing glioma rendering these tumors intrinsically resistant to antiangiogenic treatment. Intrinsic resistance to antiangiogenic therapy is defined as a non-respons
16341 records 51/1090 page Previous Next First page 上5页 5152535455 下5页 Last page